Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 13 von 22

Details

Autor(en) / Beteiligte
Titel
Polyclonal F(ab’)2 fragments of equine antibodies raised against the spike protein neutralize SARS-CoV-2 variants with high potency
Ist Teil von
  • iScience, 2021-11, Vol.24 (11), p.103315-103315, Article 103315
Ort / Verlag
United States: Elsevier Inc
Erscheinungsjahr
2021
Quelle
Alma/SFX Local Collection
Beschreibungen/Notizen
  • We used the recombinant trimeric spike (S) glycoprotein in the prefusion conformation to immunize horses for the production of hyperimmune globulins against SARS-CoV-2. Serum antibody titers measured by ELISA were above 1:106, and the neutralizing antibody titer against authentic virus (WT) was 1:14,604 (average PRNT90). Plasma from immunized animals was pepsin digested to remove the Fc portion and purified, yielding an F(ab’)2 preparation with PRNT90 titers 150-fold higher than the neutralizing titers in human convalescent plasma. Challenge studies were carried out in hamsters and showed the in vivo ability of equine F(ab’)2 to reduce viral load in the pulmonary tissues and significant clinical improvement determined by weight gain. The neutralization curve by F(ab’)2 was similar against the WT and P.2 variants, but displaced to higher concentrations by 0.39 log units against the P.1 (Gamma) variant. These results support the possibility of using equine F(ab’)2 preparation for the clinical treatment of COVID patients. [Display omitted] •Trimeric spike glycoprotein induces high level of horse neutralizing antibodies•The F(ab’)2 Ab has neutralizing titer 150-fold higher than human convalescent plasma•The neutralizing activity of F(ab’)2 was high against the P.1 (Gamma) and P.2 variants•Anti-spike F(ab’)2 protected hamsters against SARS-CoV-2 challenge Immunology; Equine immunology; Biological sciences
Sprache
Englisch
Identifikatoren
ISSN: 2589-0042
eISSN: 2589-0042
DOI: 10.1016/j.isci.2021.103315
Titel-ID: cdi_doaj_primary_oai_doaj_org_article_fd393a9b9edf40629a376603a387320c

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX